Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Bouvier

Internal Medicine Grand Blanc, MI Medical Doctor

NPI 1124011291 CMS profile 322494

5536 S Saginaw Rd, Grand Blanc, MI 48507

Open in the dashboard

General payments

$5,439

360 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Bouvier of Grand Blanc, MI is reported in the CMS Open Payments database as having received $5,439 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,511 89
2024 General $704 52
2023 General $872 57
2022 General $726 51
2021 General $943 59
2020 General $397 32
2019 General $285 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Bouvier
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Bouvier were reported at $1,511. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Bouvier Internal Medicine median Middle half National median
2019 $285 $159 $48–$570 $163
2020 $397 $119 $33–$402 $114
2021 $943 $135 $37–$521 $132
2022 $726 $141 $42–$496 $149
2023 $872 $149 $45–$519 $160
2024 $704 $154 $47–$537 $164
2025 $1,511 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $923 92 payments
  2. GlaxoSmithKline, LLC. $697 34 payments
  3. Otsuka America Pharmaceutical, Inc. $684 45 payments
  4. AstraZeneca Pharmaceuticals LP $361 24 payments
  5. Vanda Pharmaceuticals Inc. $283 17 payments
  6. Collegium Pharmaceutical, Inc. $276 19 payments
  7. Novartis Pharmaceuticals Corporation $250 15 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $248 14 payments
  9. ITI, Inc. $242 14 payments
  10. Allergan Inc. $194 18 payments
  11. Other $1,280 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,390 358 payments
  2. Education $49 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI $633 42 payments
  2. TRELEGY ELLIPTA $481 32 payments
  3. VRAYLAR Neuroscience $475 48 payments
  4. FANAPT $283 17 payments
  5. UBRELVY $271 26 payments
  6. XTAMPZA $258 18 payments
  7. BREZTRI $255 17 payments
  8. XIFAXAN $248 14 payments
  9. VRAYLAR Neuroscience $239 23 payments
  10. ENTRESTO $225 14 payments
  11. Other $2,802 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 169 drugs

Part D claims

11,442

Median for Family Practice: 1,826

Drug cost

$1,072,865

Median for Family Practice: $120,094

Branded share of claims

35.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 138 $169,844
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 126 $91,526
Trulicity Dulaglutide Brand 63 $86,927
Eliquis Apixaban Brand 97 $83,783
Oxycontin Oxycodone Hcl Brand 56 $77,592
Vraylar Cariprazine Hcl Brand 38 $69,268
Xarelto Rivaroxaban Brand 86 $66,336
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 12 $46,659
Jardiance Empagliflozin Brand 36 $41,138
Rexulti Brexpiprazole Brand 22 $32,131

The 10 drugs with the highest cost, of 169 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$115,814

Medicare's payments for the services billed

Medicare patients

162

Average age 71

Services billed

1,792

88 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 50%
COPD 31%
Diabetes 30%
Ischemic heart disease 27%
Depression 22%
Heart failure 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $163
  • Lundbeck LLC $49
$212 22 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $73
$73 126 —
VRAYLAR
  • AbbVie, Inc. $71
$71 38 —
FANAPT
  • Vanda Pharmaceuticals Inc. $48
$48 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $46
$46 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record